Boston Children’s Hospital, Blue Cross Blue Shield of Massachusetts and Blue Shield of California have all invested in the children's behavioural healthcare provider.

Scienion has agreed to a cash and share acquisition by Cellink two decades after emerging from Max Planck Institute for Molecular Genetics.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Returning investor PPD co-led a $40m round for the remote clinical trials service, while Novartis, Amgen, Sanofi and Alphabet also doubled down on their commitments.

The patient communication app developer took its total funding past the $30m mark with a round co-led by Google's Gradient Ventures fund.

Tsinghua-backed Rokae is working on lightweight robots with a wide range of applications and has now raised $43.5m altogether.

GI Windows Medical plans to put the $16.4m from the Johnson & Johnson Innovation – JJDC-backed round into clinical validation of its anastomotic endoscopy device.

Eli Lilly and WuXi Biologics-backed biologics developer Inhibrx floated at the midpoint of its range having previously raised $135m in debt and equity financing.

Dizal, co-founded by AstraZeneca three years ago to develop therapies for a broad range of diseases, pulled in $100m through a round led by Lilly Asia Ventures.